Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.

[1]  K. Sikorska,et al.  First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. , 2020 .

[2]  C. Blank,et al.  Learning from clinical trials of neoadjuvant checkpoint blockade , 2020, Nature Medicine.

[3]  B. Schilling,et al.  Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease , 2019, The British journal of dermatology.

[4]  T. Schumacher,et al.  3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial) , 2019, Annals of Oncology.

[5]  K. Shannon,et al.  18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma , 2019, Annals of Oncology.

[6]  K. Shannon,et al.  Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. , 2019, The Lancet. Oncology.

[7]  R. Scolyer,et al.  Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial. , 2019, Journal of Clinical Oncology.

[8]  G. Linette,et al.  A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma , 2019, Nature Medicine.

[9]  A. Broeks,et al.  Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma , 2018, Nature Medicine.

[10]  Merrick I Ross,et al.  Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma , 2018, Nature Medicine.

[11]  J. Taube,et al.  Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[13]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[14]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[15]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[16]  C. Garbe,et al.  Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour , 2013, PloS one.

[17]  E. Nagore,et al.  Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[19]  Tanja Fehm,et al.  Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.

[20]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.